This paper aimed to investigate the cost of the PCSK9-treated patient pathway and main barriers to patient access to medicines and to suggest some changes to this pathway.
Management of patients eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: economic impact and reform proposals
Claudio Jommi
;Marianna Cavazza
2019
Abstract
This paper aimed to investigate the cost of the PCSK9-treated patient pathway and main barriers to patient access to medicines and to suggest some changes to this pathway.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
paper_pubblicato.pdf
accesso aperto
Descrizione: Articolo
Tipologia:
Pdf editoriale (Publisher's layout)
Licenza:
Creative commons
Dimensione
984.38 kB
Formato
Adobe PDF
|
984.38 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
